Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Oct 26, 2026
TickeronGET DAILY SIGNALS
Why Is Perspective Therapeutics (CATX) Stock Down -23.60% Today?

Why Is Perspective Therapeutics (CATX) Stock Down -23.60% Today?

Key Takeaways

  • CATX shares are down roughly 23.60% in Monday's session, extending Friday's 28.76% plunge.
  • The primary driver is an RBC Capital downgrade to Sector Perform from Outperform, with its price target cut to $4 from $14.
  • The selloff continues a negative market reaction to interim Phase 1/2a data for lead asset VMT-α-NET presented at ESMO.
  • Investors are weighing lower-than-expected Cohort 2 response rates, two cases of grade 3 kidney injury, and funding risks for a future Phase 3 trial.
  • Not all analysts agree: BTIG reiterated a Buy rating and $14 target, calling the weakness a buying opportunity.
  • For more detail, explore Price Targets, Earnings, and Forecast pages for CATX.
  • To see how AI trading systems are positioned across the market, visit Trending AI Robots.

Opening Summary

Perspective Therapeutics, Inc. (CATX), a clinical-stage radiopharmaceutical company developing lead-212 (²¹²Pb)-based targeted alpha therapies for cancer, is under heavy selling pressure on Monday. Shares were last trading near $1.23, a decline of about 23.60% from the prior session's close of $1.61, extending a sharp slide that began late last week. The move comes after RBC Capital downgraded the stock, citing efficacy that landed "somewhat below expectations" in the company's lead program, while a broader reassessment of the drug's commercial and financing path continues to weigh on sentiment.

Analyst Downgrade Adds Fuel to the Selloff

The most immediate catalyst for Monday's decline is a downgrade from RBC Capital, which cut CATX to Sector Perform from Outperform and slashed its price target to $4 from $14. In a research note, the firm said it is now "more difficult to underwrite the blue sky scenario" for the stock after reviewing updated data from the Phase 1/2a trial of VMT-α-NET in patients with somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors. RBC also cited execution risks tied to future Phase 3 trial conduct, manufacturing capacity, and competitive positioning, as well as a reduced set of near-term catalysts.

Clinical Data Reaction

The downgrade follows a market reaction that began Friday, when CATX tumbled 28.76% to $1.61 after the company presented its largest and longest-follow-up dataset for VMT-α-NET (bamzireotide navoxetan) at the ESMO Congress. While the headline results showed durable disease control—a 72% 18-month progression-free survival rate and objective response rates of 33% in the 20 mCi Cohort 2 and 50% in the 24 mCi Cohort 3—investors focused on the details. Cohort 2's response rate came in below the prior data update, two patients experienced grade 3 acute kidney injury, and the company signaled a 20 mCi dose for registrational planning, trailing the higher-responding 24 mCi cohort.

Funding and Execution Concerns

Beyond the data itself, the stock's decline reflects skepticism about the path to a registrational study. As a pre-revenue, clinical-stage company, CATX faces substantial multi-year costs to advance a Phase 3 program in a slowly progressing tumor type, and analysts have flagged uncertainty around financing, potential trial delays, and competitive threats in the radiopharmaceutical space. These concerns have amplified selling pressure even among investors who view the drug's efficacy profile as encouraging.

Market Context and Trading Activity

Trading volume has been exceptionally heavy relative to the stock's typical levels. Friday's session saw roughly 5.6 million shares change hands, well above the average of about 1.2 million, and the stock now sits near its 52-week low of $1.58. The move is company-specific rather than sector-wide, driven primarily by the data readout and subsequent analyst actions. Notably, the reaction has been divisive: BTIG reiterated a Buy rating and a $14 price target, arguing that the benefit-risk profile of VMT-α-NET remains "highly compelling" and that the selloff is "overdone," with the analyst stating the firm would be buyers on weakness.

What Comes Next for CATX

Investors will be watching several catalysts in the weeks ahead. The company's next earnings report is expected in early November, and management's commentary on the Phase 3 trial design, site activation, and cash runway will be closely scrutinized. Further maturation of Cohort 3 and Cohort 4 data could either reinforce or challenge the bear case, while additional analyst revisions may continue to drive volatility. Key risks include execution on trial conduct, manufacturing scale-up, competitive dynamics in targeted radiopharmaceuticals, and the company's ability to fund registration-stage development without excessive shareholder dilution.

Trending AI Robots

Tickeron offers hundreds of AI trading bots that monitor thousands of tickers, applying a range of strategies, timeframes, and performance metrics. Only the strongest performers under current market conditions are featured in the curated Trending AI Robots section, where users can browse active bots, review their traded symbols and strategies, and follow their signals. Explore Trending AI Robots to see which automated strategies are capturing opportunities in today's market.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: CATX

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


CATX's Indicator enters downward trend

The Aroon Indicator for CATX entered a downward trend on November 18, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 259 similar instances where the Aroon Indicator formed such a pattern. In 226 of the 259 cases the stock moved lower. This puts the odds of a downward move at 87%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CATX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

The Moving Average Convergence Divergence (MACD) for CATX just turned positive on November 13, 2026. Looking at past instances where CATX's MACD turned positive, the stock continued to rise in 44 of 48 cases over the following month. The odds of a continued upward trend are 90%.

Following a +14.29% 3-day Advance, the price is estimated to grow further. Considering data from situations where CATX advanced for three days, in 211 of 265 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

CATX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.296) is normal, around the industry mean (4.142). P/E Ratio (-0.632) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (40.124).

The Tickeron Price Growth Rating for this company is 96 (best 1 - 100 worst), indicating slightly worse than average price growth. CATX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CATX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

Market Cap

The average market capitalization across the Medical/Nursing Services Industry is 6.17B. The market cap for tickers in the group ranges from 837 to 190.22B. ABT holds the highest valuation in this group at 190.22B. The lowest valued company is DHAI at 837.

High and low price notable news

The average weekly price growth across all stocks in the Medical/Nursing Services Industry was -8%. For the same Industry, the average monthly price growth was -11%, and the average quarterly price growth was -15%. POAS experienced the highest price growth at 158%, while LFWD experienced the biggest fall at -44%.

Volume

The average weekly volume growth across all stocks in the Medical/Nursing Services Industry was -40%. For the same stocks of the Industry, the average monthly volume growth was 13% and the average quarterly volume growth was -20%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 50
Price Growth Rating: 63
SMR Rating: 89
Profit Risk Rating: 94
Seasonality Score: 14 (-100 ... +100)
Trend Prediction Engine 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a producer of therapeutic radioactive isotopes

Industry MedicalNursingServices

Industry
Biotechnology
Address
2401 Elliott Avenue
Phone
+1 206 676-0900
Employees
140
Web
https://www.perspectivetherapeutics.com
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
Cerebras Systems (CBRS) dropped -6.48% to $97.43 in regular trading from the prior close of $104.18, reversing an early premarket gain of roughly +3%. No verified news or fundamental catalyst found for the intraday reversal; the move is likely profit-taking after the stock's +21% post-earnings rebound, consistent with a name that averages a ±4.5% daily swing and remains 65% below its first-day close.
CBRS fell -6.07% to $97.86 in the opening minutes of Wednesday's regular session, down from Tuesday's close of $104.18 — the move occurred during market hours, not premarket or after-hours. No verified news or fundamental catalyst found: no new filing, contract, or analyst action explains the drop, which is likely continued give-back from the post-earnings pop and the stock's habitual volatility — CBRS has averaged a ±4.5% daily swing over the past 60 sessions, and 17 of those sessions moved as much or more.
KLAR dropped -4.84% to $13.75 from Wednesday's close of $14.45, with the decline occurring during Thursday's regular session. JPMorgan downgraded the shares to Hold from Overweight and cut its price target to $17 from $20 in a note published before the open, extending a run of post-earnings target reductions.
Why Is Perspective Therapeutics (CATX) Stock Down -23.60% Today?